Clinical Trial Detail

NCT ID NCT02950038
Title Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC)
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

lung non-small cell carcinoma

Therapies

Ibrutinib + Nivolumab

Age Groups: senior adult

No variant requirements are available.